Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Bigner, DD' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 140 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Kuan, CT; Wikstrand, CJ; Bigner, DD
      EGF mutant receptor vIII as a molecular target in cancer therapy

      ENDOCRINE-RELATED CANCER
    2. Foulon, CF; Welsh, PC; Bigner, DD; Zalutsky, MR
      Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-Iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR

      NUCLEAR MEDICINE AND BIOLOGY
    3. Friedman, HS; Keir, ST; Houghton, PJ; Lawless, AA; Bigner, DD; Waters, SJ
      Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    4. Cavazos, CM; Keir, ST; Yoshinari, T; Bigner, DD; Friedman, HS
      Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxy) ethylamino-12,13-dihydro-13-(beta-D-gluco pyranosyl)5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    5. Keir, ST; Hausheer, F; Lawless, AA; Bigner, DD; Friedman, HS
      Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    6. Rich, JN; Guo, CH; McLendon, RE; Bigner, DD; Wang, XF; Counter, CM
      A genetically tractable model of human glioma formation

      CANCER RESEARCH
    7. Cokgor, I; Akabani, G; Friedman, HS; Friedman, AH; Zalutsky, MR; Zehngebot, LM; Provenzale, JM; Guy, CD; Wikstrand, CJ; Bigner, DD
      Long term response in a patient with neoplastic meningitis secondary to melanoma treated with I-131-radiolabeled antichondroitin proteoglycan sulfateMel-14 F(ab ')(2) - A case study

      CANCER
    8. Heimberger, AB; Bigner, DD; Sampson, JH
      Biological principles of brain tumor immunotherapy

      BRAIN TUMOR IMMUNOTHERAPY
    9. Wikstrand, CJ; Zalutsky, MR; Bigner, DD
      Radiolabeled antibodies for therapy of brain tumors

      BRAIN TUMOR IMMUNOTHERAPY
    10. Loging, WT; Lal, A; Siu, IM; Loney, TL; Wikstrand, CJ; Marra, MA; Prange, C; Bigner, DD; Strausberg, RL; Riggins, GJ
      Identifying potential tumor markers and antigens by database mining and rapid expression screening

      GENOME RESEARCH
    11. Heimberger, AB; Archer, GE; McLendon, RE; Hulette, C; Friedman, AH; Friedman, HS; Bigner, DD; Sampson, JH
      Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats

      CLINICAL CANCER RESEARCH
    12. Patel, VJ; Elion, GB; Houghton, PJ; Keir, S; Pegg, AE; Johnson, SP; Dolan, ME; Bigner, DD; Friedman, HS
      Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft

      CLINICAL CANCER RESEARCH
    13. Cokgor, I; Akabani, G; Kuan, CT; Friedman, HS; Friedman, AH; Coleman, RE; McLendon, RE; Bigner, SH; Zhao, XG; Garcia-Turner, AM; Pegram, CN; Wikstrand, CJ; Shafman, TD; Herndon, JE; Provenzale, JM; Zalutsky, MR; Bigner, DD
      Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas

      JOURNAL OF CLINICAL ONCOLOGY
    14. Friedman, HS; Pluda, J; Quinn, JA; Ewesuedo, RB; Long, L; Friedman, AH; Cokgor, I; Colvin, OM; Haglund, MM; Ashley, DM; Rich, JN; Sampson, J; Pegg, AE; Moschel, RC; McLendon, RE; Provenzale, JM; Stewart, ES; Tourt-Uhlig, S; Garcia-Turner, AM; Herndon, JE; Bigner, DD; Dolan, ME
      Phase I trial of carmustine plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma

      JOURNAL OF CLINICAL ONCOLOGY
    15. Akabani, G; Cokgor, I; Coleman, RE; Trotter, DG; Wong, TZ; Friedman, HS; Friedman, AH; Garcia-Turner, A; Herndon, JE; DeLong, D; McLendon, RE; Zhao, XG; Pegram, CN; Provenzale, JM; Bigner, DD; Zalutsky, MR
      Dosimetry and dose-response relationships in newly diagnosed patients withmalignant gliomas treated with iodine-131-labeled anti-tenascin monoclonalantibody 81C6 therapy

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    16. Friedman, HS; Castellino, RC; Elion, GB; Keir, ST; Houghton, PJ; Johnson, SP; Bigner, DD
      Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts (vol 45, pg 345, 1999)

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    17. Keir, ST; Dolan, ME; Pegg, AE; Lawless, A; Moschel, RC; Bigner, DD; Friedman, HS
      O-6-benzylguanine-mediated enhancement of nitrosourea activity in Mer(-) central nervous system tumor xenografts - implications for clinical trials

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    18. Friedman, HS; Castellino, RC; Elion, GB; Keir, ST; Houghton, PJ; Johnson, SP; Bigner, DD
      Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    19. Heimberger, AB; Crotty, LE; Archer, GE; McLendon, RE; Friedman, A; Dranoff, G; Bigner, DD; Sampson, JH
      Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma

      JOURNAL OF NEUROIMMUNOLOGY
    20. Sampson, JH; Crotty, LE; Lee, S; Archer, GE; Ashley, DM; Wikstrandt, CJ; Hale, LP; Small, C; Dranoff, G; Friedman, AH; Friedman, HS; Bigner, DD
      Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    21. McLendon, RE; Wikstrand, CJ; Matthews, MR; Al-Baradei, R; Bigner, SH; Bigner, DD
      Glioma-associated antigen expression in oligodendroglial neoplasms: Tenascin and epidermal growth factor receptor

      JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
    22. Kuan, CT; Wikstrand, CJ; Archer, G; Beers, R; Pastan, I; Zalutsky, MR; Bigner, DD
      Increased binding affinity enhances targeting of glioma xenografts by EGFRVIII-specific scFv

      INTERNATIONAL JOURNAL OF CANCER
    23. Foulon, CF; Reist, CJ; Bigner, DD; Zalutsky, MR
      Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody

      CANCER RESEARCH
    24. Campa, MJ; Kuan, CT; O'Connor-McCourt, MD; Bigner, DD; Patz, EF
      Design of a novel small peptide targeted against a tumor-specific receptor

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    25. Aldosari, N; Rasheed, BKA; McLendon, RE; Friedman, HS; Bigner, DD; Bigner, SH
      Characterization of chromosome 17 abnormalities in medulloblastomas

      ACTA NEUROPATHOLOGICA
    26. Archer, GE; Sampson, JH; Lorimer, IAJ; McLendon, RE; Kuan, CT; Friedman, AH; Friedman, HS; Pastan, IH; Bigner, DD
      Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1

      CLINICAL CANCER RESEARCH
    27. Kuan, CT; Reist, CJ; Foulon, CF; Lorimer, IAJ; Archer, G; Pegram, CN; Pastan, I; Zalutsky, MR; Bigner, DD
      I-125-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts

      CLINICAL CANCER RESEARCH
    28. Sampson, JH; Archer, GE; Villavicencio, AT; McLendon, RE; Friedman, AH; Bishop, WR; Bigner, DD; Friedman, HS
      Treatment of neoplastic meningitis with intrathecal temozolomide

      CLINICAL CANCER RESEARCH
    29. Foulon, CF; Bigner, DD; Zalutsky, MR
      Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications

      BIOCONJUGATE CHEMISTRY
    30. Reist, CJ; Foulon, CF; Alston, K; Bigner, DD; Zalutsky, MR
      Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[At-211]astato-3-pyridinecarboxylate

      NUCLEAR MEDICINE AND BIOLOGY
    31. Friedman, HS; Petros, WP; Friedman, AH; Schaaf, LJ; Kerby, T; Lawyer, J; Parry, M; Houghton, PJ; Lovell, S; Rasheed, K; Cloughsey, T; Stewart, ES; Colvin, OM; Provenzale, JM; McLendon, RE; Bigner, DD; Cokgor, I; Haglund, M; Rich, J; Ashley, D; Malczyn, J; Elfring, GL; Miller, LL
      Irinotecan therapy in adults with recurrent or progressive malignant glioma

      JOURNAL OF CLINICAL ONCOLOGY
    32. McLendon, RE; Archer, GE; Larsen, RH; Akabani, G; Bigner, DD; Zalutsky, MR
      Radiotoxicity of systemically administered At-211-labeled human/mouse chimeric monoclonal antibody: A long-term survival study with histologic analysis

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    33. Dong, Q; Johnson, SP; Colvin, OM; Bullock, N; Kilborn, C; Runyon, G; Sullivan, DM; Easton, J; Bigner, DD; Nahta, R; Marks, J; Modrich, P; Friedman, HS
      Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR)

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    34. Friedman, HS; Pegg, AE; Johnson, SP; Loktionova, NA; Dolan, ME; Modrich, P; Moschel, RC; Struck, R; Brent, TP; Ludeman, S; Bullock, N; Kilborn, C; Keir, S; Dong, Q; Bigner, DD; Colvin, OM
      Modulation of cyclophosphamide activity by O-6-alkylguanine-DNA alkyltransferase

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    35. Wikstrand, CJ; Cokgor, I; Sampson, JH; Bigner, DD
      Monoclonal antibody therapy of human gliomas: Current status and future approaches

      CANCER AND METASTASIS REVIEWS
    36. Archer, GE; Sampson, JH; McLendon, RE; Friedman, AH; Colvin, OM; Rose, M; Sands, H; McCullough, W; Fuchs, HE; Bigner, DD; Friedman, HS
      Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats

      JOURNAL OF NEURO-ONCOLOGY
    37. Akabani, G; Reist, CJ; Cokgor, I; Friedman, AH; Friedman, HS; Coleman, RE; Zhao, XG; Bigner, DD; Zalutsky, MR
      Dosimetry of I-131-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors

      JOURNAL OF NUCLEAR MEDICINE
    38. Rich, JN; Zhang, M; Datto, MB; Bigner, DD; Wang, XF
      Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines

      JOURNAL OF BIOLOGICAL CHEMISTRY
    39. Bigner, SH; Matthews, MR; Rasheed, BKA; Wiltshire, RN; Friedman, HS; Friedman, AH; Stenzel, TT; Dawes, DM; McLendon, RE; Bigner, DD
      Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization

      AMERICAN JOURNAL OF PATHOLOGY
    40. WIKSTRAND CJ; REIST CJ; ARCHER GE; ZALUTSKY MR; BIGNER DD
      THE CLASS-III VARIANT OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR (EGFRVIII) - CHARACTERIZATION AND UTILIZATION AS AN IMMUNOTHERAPEUTIC TARGETS

      Journal of neurovirology
    41. LEE SE; JOHNSON SP; HALE LP; LI J; BULLOCK N; FUCHS H; FRIEDMAN A; MCLENDON R; BIGNER DD; MODRICH P; FRIEDMAN HS
      ANALYSIS OF DNA MISMATCH REPAIR PROTEINS IN HUMAN MEDULLOBLASTOMA

      Clinical cancer research
    42. REIST CJ; BIGNER DD; ZALUTSKY MR
      HUMAN IGG2 CONSTANT-REGION ENHANCES IN-VIVO STABILITY OF ANTI-TENASCIN ANTIBODY 81C6 COMPARED WITH ITS MURINE PARENT

      Clinical cancer research
    43. BIGNER DD; BROWN MT; FRIEDMAN AH; COLEMAN RE; AKABANI G; FRIEDMAN HS; THORSTAD WL; MCLENDON RE; BIGNER SH; ZHAO XG; PEGRAM CN; WIKSTRAND CJ; HERNDON JE; VICK NA; PALEOLOGOS N; COKGOR I; PROVENZALE JM; ZALUTSKY MR
      IODINE-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 TREATMENT OFPATIENTS WITH RECURRENT MALIGNANT GLIOMAS - PHASE-I TRIAL RESULTS

      Journal of clinical oncology
    44. FRIEDMAN HS; KOKKINAKIS DM; PLUDA J; FRIEDMAN AH; COKGOR I; HAGLUND MM; ASHLEY DM; RICH J; DOLAN ME; PEGG AE; MOSCHEL RC; MCLENDON RE; KERBY T; HERNDON JE; BIGNER DD; SCHOLD SC
      PHASE-I TRIAL OF O-6-BENZYLGUANINE FOR PATIENTS UNDERGOING SURGERY FOR MALIGNANT GLIOMA

      Journal of clinical oncology
    45. Friedman, HS; McLendon, RE; Kerby, T; Dugan, M; Bigner, SH; Henry, AJ; Ashley, DM; Krischer, J; Lovell, S; Rasheed, K; Marchev, F; Seman, AJ; Cokgor, I; Rich, J; Stewart, E; Colvin, OM; Provenzale, JM; Bigner, DD; Haglund, MM; Friedman, AH; Modrich, PL
      DNA mismatch repair and O-6-alkylguanine-DNA alkyltransferase analysis andresponse to temodal in newly diagnosed malignant glioma

      JOURNAL OF CLINICAL ONCOLOGY
    46. HANLEY ML; ELION GB; COLVIN OM; MODRICH PL; KEIR S; ADAMS DJ; BIGNER DD; FRIEDMAN HS
      THERAPEUTIC EFFICACY OF VINORELBINE AGAINST PEDIATRIC AND ADULT CENTRAL-NERVOUS-SYSTEM TUMORS

      Cancer chemotherapy and pharmacology
    47. COGGINS CA; ELION GB; HOUGHTON PJ; HARE CB; KEIR S; COLVIN OM; BIGNER DD; FRIEDMAN HS
      ENHANCEMENT OF IRINOTECAN (CPT-11) ACTIVITY AGAINST CENTRAL-NERVOUS-SYSTEM TUMOR XENOGRAFTS BY ALKYLATING-AGENTS

      Cancer chemotherapy and pharmacology
    48. ASHLEY DM; SAMPSON JH; ARCHER GE; HALE LP; BIGNER DD
      LOCAL PRODUCTION OF TGF-BETA-1 INHIBITS CEREBRAL EDEMA, ENHANCES TNF-ALPHA INDUCED APOPTOSIS AND IMPROVES SURVIVAL IN A MURINE GLIOMA MODEL

      Journal of neuroimmunology
    49. REIST CJ; BIGNER DD; ZALUTSKY MR
      HUMAN IGG(2) CONSTANT-REGION ENHANCES THE IN-VIVO STABILITY OF MONOCLONAL-ANTIBODY 81C6 COMPARED TO ITS MURINE PARENT

      The Journal of nuclear medicine
    50. FOULON CF; BIGNER DD; ZALUTSKY MR
      PRETARGETED RADIOIMMUNOTHERAPY USING ANTI-TENASCIN 81C6-STREPTAVIDIN CONJUGATES AND RADIOLABELED BIOTIN - PREPARATION OF REAGENTS

      The Journal of nuclear medicine
    51. COKGOR I; AKABANI G; BROWN MT; FRIEDMAN AH; COLEMAN RE; FRIEDMAN HS; THORSTAD WL; MCLENDON RE; BIGNER SH; ZHAO XG; PEGRAM CN; WIKSTRAND CJ; HERNDON JE; VICK NA; PALEOLOGOS N; ZALUTSKY MR; BIGNER DD
      RESULTS OF A PHASE-I TRIAL OF PATIENTS WITH RECURRENT BRAIN-TUMORS AND PRIOR RADIATION-THERAPY TREATED WITH I-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 VIA SURGICALLY CREATED RESECTION CAVITIES

      Neurology
    52. MCLENDON RE; CLEVELAND L; PEGRAM C; BIGNER SH; BIGNER DD; FRIEDMAN HS
      IMMUNOHISTOCHEMICAL DETECTION OF THE DNA-REPAIR ENZYME O-6-METHYLGUANINE-DNA METHYLTRANSFERASE IN FORMALIN-FIXED, PARAFFIN-EMBEDDED ASTROCYTOMAS

      Laboratory investigation
    53. MATTHEWS MR; RASHEED BKA; MCLENDON RE; WIKSTRAND CJ; BIGNER DD; BIGNER SH
      MOLECULAR AND IMMUNOHISTOLOGIC (IHC) STUDIES ON OLIGODENDROGLIAL (O) TUMORS

      Journal of neuropathology and experimental neurology
    54. ASHLEY DM; KONG FM; BIGNER DD; HALE LP
      ENDOGENOUS EXPRESSION OF TRANSFORMING-GROWTH-FACTOR BETA-1 INHIBITS GROWTH AND TUMORIGENICITY AND ENHANCES FAS-MEDIATED APOPTOSIS IN A MURINE HIGH-GRADE GLIOMA MODEL

      Cancer research
    55. WIKSTRAND CJ; BIGNER DD
      PROGNOSTIC APPLICATIONS OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR AND ITS LIGAND, TRANSFORMING GROWTH-FACTOR-ALPHA

      Journal of the National Cancer Institute
    56. ARCHER GE; SAMPSON JH; BIGNER DD
      VIRUSES AND ONCOGENES IN BRAIN-TUMORS

      Journal of neurovirology
    57. ASHLEY DM; BIGNER DD
      RECENT ADVANCES IN THE BIOLOGY OF CENTRAL-NERVOUS-SYSTEM TUMORS

      Current opinion in neurology
    58. HAUCK ML; DEWHIRST MW; BIGNER DD; ZALUTSKY MR
      LOCAL HYPERTHERMIA IMPROVES UPTAKE OF A CHIMERIC MONOCLONAL-ANTIBODY IN A SUBCUTANEOUS XENOGRAFT MODEL

      Clinical cancer research
    59. REIST CJ; BATRA SK; PEGRAM CN; BIGNER DD; ZALUTSKY MR
      IN-VITRO AND IN-VIVO BEHAVIOR OF RADIOLABELED CHIMERIC ANTI-EGFRVIII MONOCLONAL-ANTIBODY - COMPARISON WITH ITS MURINE PARENT

      Nuclear medicine and biology
    60. ZALUTSKY MR; STABIN MG; LARSEN RH; BIGNER DD
      TISSUE DISTRIBUTION AND RADIATION-DOSIMETRY OF ASTATINE-211-LABELED CHIMERIC 81C6, AN ALPHA-PARTICLE-EMITTING IMMUNOCONJUGATE

      Nuclear medicine and biology
    61. BEAN JM; ARCHER GE; MUNLEY MT; ONG E; SNYDER SA; HAROON ZA; MCLENDON RE; MARKS LB; STRATFORD MRL; CHAPLIN DJ; BRIZEL DM; BIGNER DD; DEWHIRST MW
      THE IMPACT OF HYPOXIA AND OXYGENATION MODIFICATION ON THE RADIATION RESPONSE OF AN INTRACRANIAL RAT GLIOMA

      International journal of radiation oncology, biology, physics
    62. HARE CB; ELION GB; COLVIN OM; ALIOSMAN F; GRIFFITH OW; PETROS WP; KEIR S; MARCELLI SL; BIGNER DD; FRIEDMAN HS
      CHARACTERIZATION OF THE MECHANISMS OF BUSULFAN RESISTANCE IN A HUMAN GLIOBLASTOMA-MULTIFORME XENOGRAFT

      Cancer chemotherapy and pharmacology
    63. KURPAD SN; DOLAN ME; MCLENDON RE; ARCHER GE; MOSCHEL RC; PEGG AE; BIGNER DD; FRIEDMAN HS
      INTRAARTERIAL O-6-BENZYLGUANINE ENABLES THE SPECIFIC THERAPY OF NITROSOUREA-RESISTANT INTRACRANIAL HUMAN GLIOMA XENOGRAFTS IN ATHYMIC RATS WITH 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA

      Cancer chemotherapy and pharmacology
    64. MOYNIHAN K; ELION GB; PEGRAM C; REIST CJ; WELLNER D; BIGNER DD; GRIFFITH OW; FRIEDMAN HS
      L-AMINO-ACID OXIDASE (LOX) MODULATION OF MELPHALAN ACTIVITY AGAINST INTRACRANIAL GLIOMA

      Cancer chemotherapy and pharmacology
    65. HARE CB; ELION GB; HOUGHTON PJ; HOUGHTON JA; MARCELLI SL; KEIR S; BIGNER DD; FRIEDMAN HS
      THERAPEUTIC EFFICACY OF THE TOPOISOMERASE-I INHIBITOR PIPERIDINO]-1-PIPERIDINO)-CARBONYLOXY-CAMPTOTHECIN AGAINST PEDIATRIC AND ADULT CENTRAL-NERVOUS-SYSTEM TUMOR XENOGRAFTS

      Cancer chemotherapy and pharmacology
    66. CHU CT; EVERISS KD; WIKSTRAND CJ; BATRA SK; KUNG HJ; BIGNER DD
      RECEPTOR DIMERIZATION IS NOT A FACTOR IN THE SIGNALING ACTIVITY OF A TRANSFORMING VARIANT EPIDERMAL GROWTH-FACTOR RECEPTOR (EGFRVIII)

      Biochemical journal
    67. ASHLEY DM; BATRA SK; BIGNER DD
      MONOCLONAL-ANTIBODIES TO GROWTH-FACTORS AND GROWTH-FACTOR RECEPTORS -THEIR DIAGNOSTIC AND THERAPEUTIC POTENTIAL IN BRAIN-TUMORS

      Journal of neuro-oncology
    68. ASHLEY DM; SAMPSON JH; ARCHER GE; BATRA SK; BIGNER DD; HALE LP
      A GENETICALLY-MODIFIED ALLOGENEIC CELLULAR VACCINE GENERATES MHC CLASS I-RESTRICTED CYTOTOXIC RESPONSES AGAINST TUMOR-ASSOCIATED ANTIGENS AND PROTECTS AGAINST CNS TUMORS IN-VIVO

      Journal of neuroimmunology
    69. REIST CJ; FOULON CF; BIGNER DD; ZALUTSKY MR
      A METHOD FOR LABELING INTERNALIZING ANTIBODIES WITH ASTATINE-211

      The Journal of nuclear medicine
    70. AKABANI G; THORSTAD WL; BROWN MT; COLEMAN RE; ZALUTSKY MR; BIGNER DD
      DOSIMETRY METHODS FOR PATIENTS WITH MALIGNANT CNS TUMORS TREATED WITHI-131 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY

      The Journal of nuclear medicine
    71. SAMPSON JH; ASHLEY DM; ARCHER GE; FUCHS HE; DRANOFF G; HALE LP; BIGNER DD
      CHARACTERIZATION OF SPONTANEOUS MURINE ASTROCYTOMA AND ABROGATION OF ITS TUMORIGENICITY BY CYTOKINE SECRETION

      Neurosurgery
    72. BIGNER DD; SAMPSON JH
      INTRAVENTRICULAR IMMUNOTOXIN THERAPY FOR LEPTOMENINGEAL NEOPLASIA - COMMENT

      Neurosurgery
    73. ASHLEY DM; FAIOLA B; NAIR S; HALE LP; BIGNER DD; GILBOA E
      BONE MARROW-GENERATED DENDRITIC CELLS PULSED WITH TUMOR EXTRACTS OR TUMOR RNA INDUCE ANTITUMOR IMMUNITY AGAINST CENTRAL-NERVOUS-SYSTEM TUMORS

      The Journal of experimental medicine
    74. REIST CJ; ARCHER GE; WIKSTRAND CJ; BIGNER DD; ZALUTSKY MR
      IMPROVED TARGETING OF AN ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR VARIANT-III MONOCLONAL-ANTIBODY IN TUMOR XENOGRAFTS AFTER LABELING USING N-SUCCINIMIDYL 5-IODO-3-PYRIDINECARBOXYLATE

      Cancer research
    75. RASHEED BKA; STENZEL TT; MCLENDON RE; PARSONS R; FRIEDMAN AH; FRIEDMAN HS; BIGNER DD; BIGNER SH
      PTEN GENE-MUTATIONS ARE SEEN IN HIGH-GRADE BUT NOT IN LOW-GRADE GLIOMAS

      Cancer research
    76. WIKSTRAND CJ; MCLENDON RE; FRIEDMAN AH; BIGNER DD
      CELL-SURFACE LOCALIZATION AND DENSITY OF THE TUMOR-ASSOCIATED VARIANTOF THE EPIDERMAL GROWTH-FACTOR RECEPTOR, EGFRVIII

      Cancer research
    77. FRIEDMAN HS; JOHNSON SP; DONG Q; SCHOLD SC; RASHEED BKA; BIGNER SH; ALIOSMAN F; DOLAN E; COLVIN OM; HOUGHTON P; GERMAIN G; DRUMMOND JT; KEIR S; MARCELLI S; BIGNER DD; MODRICH P
      METHYLATOR RESISTANCE MEDIATED BY MISMATCH REPAIR DEFICIENCY IN A GLIOBLASTOMA-MULTIFORME XENOGRAFT

      Cancer research
    78. BROWN MT; COLEMAN RE; FRIEDMAN AH; FRIEDMAN HS; MCLENDON RE; REIMAN R; FELSBERG GJ; TIEN RD; BIGNER SH; ZALUTSKY MR; ZHAO XG; WIKSTRAND CJ; PEGRAM CN; HERNDON JE; VICK NA; PALEOLOGOS N; FREDERICKS RK; SCHOLD SC; BIGNER DD
      INTRATHECAL I-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 TREATMENT OF PATIENTS WITH LEPTOMENINGEAL NEOPLASMS OR PRIMARY BRAIN-TUMOR RESECTION CAVITIES WITH SUBARACHNOID COMMUNICATION - PHASE-I TRIAL RESULTS

      Clinical cancer research
    79. ZALUTSKY MR; ARCHER GE; GARG PK; BATRA SK; BIGNER DD
      CHIMERIC ANTI-TENASCIN ANTIBODY 81C6 - INCREASED TUMOR-LOCALIZATION COMPARED WITH ITS MURINE PARENT

      Nuclear medicine and biology
    80. MCLENDON RE; ARCHER GE; GARG PK; BIGNER DD; ZALUTSKY MR
      RADIOTOXICITY OF SYSTEMICALLY ADMINISTERED [AT-211]ASTATIDE IN B6C3F1AND BALB C (NU/NU) MICE - A LONG-TERM SURVIVAL STUDY WITH HISTOLOGIC ANALYSIS/

      International journal of radiation oncology, biology, physics
    81. MOYNIHAN K; ELION GB; ALIOSMAN F; MARCELLI S; KEIR S; BIGNER DD; FRIEDMAN HS
      ENHANCEMENT OF MELPHALAN ACTIVITY BY INHIBITION OF DNA POLYMERASE-ALPHA AND DNA POLYMERASE-BETA

      Cancer chemotherapy and pharmacology
    82. DONG Q; BULLOCK N; ALIOSMAN F; COLVIN OM; BIGNER DD; FRIEDMAN HS
      REPAIR ANALYSIS OF 4-HYDROPEROXYCYCLOPHOSPHAMIDE-INDUCED DNA INTERSTRAND CROSS-LINKING IN THE C-MYC GENE IN 4-HYDROPEROXYCYCLOPHAMIDE-SENSITIVE AND 4-HYDROPEROXYCYCLOPHAMIDE-RESISTANT MEDULLOBLASTOMA CELL-LINES

      Cancer chemotherapy and pharmacology
    83. ZALUTSKY MR; BIGNER DD
      RADIOIMMUNOTHERAPY WITH ALPHA-PARTICLE EMITTING RADIOIMMUNOCONJUGATES

      Acta oncologica
    84. FREDMAN P; WIKSTRAND CJ; MANSSON JE; REIFENBERGER G; BIGNER SH; RASHEED A; SVENNERHOLM L; BIGNER DD
      IN-VIVO GROWTH-CONDITIONS SUPPRESS THE EXPRESSION OF GANGLIOSIDE GM2 AND FAVOR THAT OF LACTO SERIES GANGLIOSIDES IN THE HUMAN GLIOMA D-54MGCELL-LINE

      Glycoconjugate journal
    85. DAVIS FG; MALINSKI N; HAENSZEL W; CHANG J; FLANNERY J; GERSHMAN S; DIBBLE R; BIGNER DD
      PRIMARY BRAIN-TUMOR INCIDENCE RATES IN 4 UNITED-STATES REGIONS, 1985-1989 - A PILOT-STUDY

      Neuroepidemiology
    86. REIST CJ; GARG PK; ALSTON KL; BIGNER DD; ZALUTSKY MR
      A METHOD FOR THE RADIOHALOGENATION OF INTERNALIZING ANTIBODIES

      The Journal of nuclear medicine
    87. MCCOWAGE G; TIEN R; MCLENDON R; FELSBERG G; FUCHS H; GRAHAM ML; KURTZBERG J; MOGHRABI A; FERRELL L; KERBY T; DUNCANBROWN M; STEWART E; ROBERTSON PL; COLVIN OM; GOLEMBE B; BIGNER DD; FRIEDMAN HS
      SUCCESSFUL TREATMENT OF CHILDHOOD PILOCYTIC ASTROCYTOMAS METASTATIC TO THE LEPTOMENINGES WITH HIGH-DOSE CYCLOPHOSPHAMIDE

      Medical and pediatric oncology
    88. ASHLEY DM; LONGEE D; TIEN R; FUCHS H; GRAHAM ML; KURTZBERG O; CASEY J; OLSON J; MEIER L; FERRELL L; KERBY T; DUNCANBROWN M; STEWART E; COLVIN OM; PIPAS JM; MCCOWAGE G; MCLENDON R; BIGNER DD; FRIEDMAN HS
      TREATMENT OF PATIENTS WITH PINEALOBLASTOMA WITH HIGH-DOSE CYCLOPHOSPHAMIDE

      Medical and pediatric oncology
    89. BROWN MT; COLEMAN RE; FRIEDMAN AF; FRIEDMAN HS; PERRY JR; MCLENDON RE; BIGNER SH; ZALUTSKY MR; SCHOLD SC; BIGNER DD
      PHASE-I STUDIES OF RADIOLABELED I-131 81C6 ANTI-TENASCIN MONOCLONAL-ANTIBODY IN PATIENTS WITH RECURRENT CYSTIC GLIOMAS OR SURGICALLY CREATED BRAIN-TUMOR RESECTION CAVITIES - PRELIMINARY-RESULTS

      Neurology
    90. LORIMER IAJ; KEPPLERHAFKEMEYER A; BEERS RA; PEGRAM CN; BIGNER DD; PASTAN I
      RECOMBINANT IMMUNOTOXINS SPECIFIC FOR A MUTANT EPIDERMAL GROWTH-FACTOR RECEPTOR - TARGETING WITH A SINGLE-CHAIN ANTIBODY VARIABLE DOMAIN ISOLATED BY PHAGE DISPLAY

      Proceedings of the National Academy of Sciences of the United Statesof America
    91. SAMPSON JH; ARCHER GE; ASHLEY DM; FUCHS HE; HALE LP; DRANOFF G; BIGNER DD
      SUBCUTANEOUS VACCINATION WITH IRRADIATED, CYTOKINE-PRODUCING TUMOR-CELLS STIMULATES CD8(-MEDIATED-IMMUNITY AGAINST TUMORS LOCATED IN THE IMMUNOLOGICALLY PRIVILEGED CENTRAL-NERVOUS-SYSTEM() CELL)

      Proceedings of the National Academy of Sciences of the United Statesof America
    92. MCLENDON RE; FUNG KM; BENTLEY RC; RASHEED BKA; TROJANOWSKI JQ; BIGNER SH; BIGNER DD; FRIEDMAN HS
      PRODUCTION AND CHARACTERIZATION OF 2 EPENDYMOMA XENOGRAFTS

      Journal of neuropathology and experimental neurology
    93. REIST CJ; GARG PK; ALSTON KL; BIGNER DD; ZALUTSKY MR
      RADIOIODINATION OF INTERNALIZING MONOCLONAL-ANTIBODIES USING N-SUCCINIMIDYL 5-IODO-3-PYRIDINECARBOXYLATE

      Cancer research
    94. BARSKY D; DONG Q; COLVIN ME; MELIUS CF; LUDEMAN SM; COLVIN OM; BIGNER DD; MODRICH P; FRIEDMAN HS
      A STRUCTURAL BASIS FOR A PHOSPHORAMIDE MUSTARD-INDUCED DNA INTERSTRAND CROSS-LINK AT 5'D(GAC)

      Biophysical journal
    95. LORIMER IAJ; WIKSTRAND CJ; BATRA SK; BIGNER DD; PASTAN I
      IMMUNOTOXINS THAT TARGET AN ONCOGENIC MUTANT EPIDERMAL GROWTH-FACTOR RECEPTOR EXPRESSED IN HUMAN TUMORS

      Clinical cancer research
    96. BIGNER DD; ARCHER GE; MCLENDON RE; FRIEDMAN HS; FUCHS HE; PAI LH; HERNDON JE; PASTAN IH
      EFFICACY OF COMPARTMENTAL ADMINISTRATION OF IMMUNOTOXIN LMB-1 (B3-LYSPE38) IN A RAT MODEL OF CARCINOMATOUS MENINGITIS

      Clinical cancer research
    97. BATRA SK; CASTELINOPRABHU S; WIKSTRAND CJ; ZHU XP; HUMPHREY PA; FRIEDMAN HS; BIGNER DD
      EPIDERMAL GROWTH-FACTOR LIGAND-INDEPENDENT, UNREGULATED, CELL-TRANSFORMING POTENTIAL OF A NATURALLY-OCCURRING HUMAN MUTANT EGFRVIII GENE

      Cell growth & differentiation
    98. RASHEED BKA; MCLENDON RE; FRIEDMAN HS; FRIEDMAN AH; FUCHS HE; BIGNER DD; BIGNER SH
      CHROMOSOME-10 DELETION MAPPING IN HUMAN GLIOMAS - A COMMON DELETION REGION IN 10Q25

      Oncogene
    99. KURPAD SN; ZHAO XG; WIKSTRAND CJ; BATRA SK; MCLENDON RE; BIGNER DD
      TUMOR-ANTIGENS IN ASTROCYTIC GLIOMAS

      Glia
    100. RICH JN; ELION GB; WELLNER D; COLVIN OM; GROOTHUIS DR; HILTON JH; SCHLAGETER KE; BIGNER DD; GRIFFITH OW; FRIEDMAN HS
      THE EFFECT OF L-AMINO-ACID OXIDASE ON ACTIVITY OF MELPHALAN AGAINST AN INTRACRANIAL XENOGRAFT

      Cancer chemotherapy and pharmacology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/10/20 alle ore 06:47:18